• Definition: A heterogeneous group of congenital disorders characterized by the presence of lesions involving structures derived from the embryonic ectoderm (Skin and Central Nervous System).
  • Pathogenesis: Most are caused by defects in tumor suppressor genes, leading to hamartomas or neoplasms.
  • Inheritance: Majority are Autosomal Dominant (NF1, NF2, TSC, VHL), though spontaneous mutations are common. Some are Autosomal Recessive (Ataxia Telangiectasia) or Sporadic (Sturge-Weber).

I. Neurofibromatosis Type 1 (Von Recklinghausen Disease)

The most common neurocutaneous syndrome (1:3000).

1. Genetics

  • Gene: NF1 tumor suppressor gene on Chromosome 17q11.2.
  • Protein: Neurofibromin (regulates RAS-MAPK pathway).
  • Inheritance: Autosomal Dominant (50% are de novo mutations).

2. Diagnostic Criteria (NIH Consensus) Diagnosis requires 2 of the following 7 features:

  1. Café-au-lait (CAL) Macules: 6 spots. (Prepubertal: >5mm; Postpubertal: >15mm).
  2. Axillary or Inguinal Freckling: (Crowe’s sign).
  3. Neurofibromas: 2 of any type or 1 Plexiform Neurofibroma.
  4. Optic Glioma: Tumor of the optic pathway (often asymptomatic).
  5. Lisch Nodules: 2 iris hamartomas (seen on slit-lamp exam).
  6. Bone Lesions: Distinctive osseous lesion (sphenoid dysplasia or tibial pseudarthrosis).
  7. Family History: First-degree relative with NF1.

3. Systemic Complications

  • Neurologic: Learning disabilities (40–60%), ADHD, seizures (rare), unidentified bright objects (UBOs) on MRI.
  • Malignancy: Malignant Peripheral Nerve Sheath Tumor (MPNST), Pheochromocytoma, Leukemia (JMML).
  • Orthopedic: Scoliosis, short stature.
  • Vascular: Renal artery stenosis (Hypertension), Moyamoya syndrome.

II. Tuberous Sclerosis Complex (TSC)

Second most common; characterized by hamartomas in multiple organs.

1. Genetics

  • Genes: TSC1 (Ch 9q34, Hamartin) or TSC2 (Ch 16p13, Tuberin).
  • Mechanism: Failure to inhibit the mTOR pathway uncontrolled cell growth.
  • Inheritance: Autosomal Dominant (2/3 sporadic).

2. Clinical Features (Vogt’s Triad: Epilepsy, ID, Adenoma Sebaceum)

  • Dermatologic (Major Criteria):
    • Hypomelanotic Macules (Ash-Leaf Spots): Earliest sign; seen with Wood’s lamp.
    • Facial Angiofibromas: Malar rash (butterfly distribution); appear age 4–6 yrs.
    • Shagreen Patch: Leathery connective tissue nevus (lumbosacral).
    • Ungual Fibromas: Koenen tumors.
  • Neurologic:
    • Epilepsy (>90%): Infantile Spasms (West syndrome) are classic. Focal seizures later.
    • Pathology: Cortical Tubers, Subependymal Nodules (SEN).
    • SEGA (Subependymal Giant Cell Astrocytoma): Can cause obstructive hydrocephalus.
  • Systemic:
    • Cardiac: Rhabdomyomas (often regress spontaneously).
    • Renal: Angiomyolipomas (bleed risk).
    • Pulmonary: Lymphangioleiomyomatosis (LAM) in adult females.

3. Management

  • Seizures: Vigabatrin (Drug of choice for Infantile Spasms in TSC).
  • mTOR Inhibitors: Everolimus/Sirolimus for SEGA and large renal AMLs.

III. Sturge-Weber Syndrome (Encephalotrigeminal Angiomatosis)

A vascular neurocutaneous syndrome.

1. Genetics

  • Mutation: Somatic activating mutation in GNAQ gene.
  • Inheritance: Sporadic (Not inherited).

2. Clinical Features

  • Cutaneous: Port-Wine Stain (Nevus Flammeus). Capillary malformation in the distribution of CN V1 (Ophthalmic branch).
  • Neurologic:
    • Leptomeningeal Angioma: Ipsilateral to skin lesion.
    • Seizures: Focal motor seizures (contralateral) starting in infancy; often refractory.
    • Calcification: “Tram-track” cortical calcifications (gyriform) on CT/X-ray.
    • Deficits: Contralateral hemiparesis, hemianopia, intellectual disability.
  • Ocular: Glaucoma (Buphthalmos) in ~50% (ipsilateral).

3. Management

  • Seizures: Aggressive control (sometimes requires hemispherectomy).
  • Skin: Pulsed dye laser.
  • Eye: Annual screening for intraocular pressure.

IV. Neurofibromatosis Type 2 (NF2)

“MISME” Syndrome (Multiple Inherited Schwannomas, Meningiomas, and Ependymomas).

  • Gene: NF2 on Chromosome 22q12. Protein: Merlin (Schwannomin).
  • Hallmark: Bilateral Vestibular Schwannomas (Acoustic Neuromas).
  • Presentation: Hearing loss, tinnitus, balance issues (adolescence/young adult).
  • Skin: Fewer CAL spots than NF1; skin plaques.

V. Ataxia Telangiectasia

A combined neurocutaneous and immunodeficiency disorder.

  • Genetics: ATM gene on Ch 11q22 (DNA repair defect). Autosomal Recessive.
  • Clinical Features:
    • Ataxia: Cerebellar ataxia begins when walking starts (1–2 yrs).
    • Telangiectasia: Ocular (bulbar conjunctiva) appears age 3–6 yrs.
    • Immunity: T-cell and B-cell deficiency (low IgA/IgE) sinopulmonary infections.
    • Sensitivity: Extreme sensitivity to ionizing radiation (avoid X-rays).
  • Markers: Elevated Alpha-Fetoprotein (AFP).

VI. Other Rare Syndromes

SyndromeGeneticsKey Features
Von Hippel-Lindau (VHL)VHL (3p25), AD• Hemangioblastomas (Cerebellum/Retina)
• Renal Cell Carcinoma
• Pheochromocytoma
Incontinentia PigmentiNEMO (Xq28), X-linked Dom• Lethal in males.
4 Stages: Vesicular Verrucous Hyperpigmented (Marble cake swirls) Atrophic.
• Seizures, microcephaly.
Hypomelanosis of ItoChromosomal Mosaicism• “Incontinentia Pigmenti Achromians”
• Hypopigmented streaks along Lines of Blaschko.
• ID, Seizures in 50%.
Linear Sebaceous NevusSomatic Mosaicism• Yellow/orange alopecia plaque on scalp.
• Associated with hemimegalencephaly/seizures.

VII. Approach to a Child with Neurocutaneous Markers

  1. Detailed Skin Exam: Wood’s lamp for hypopigmented macules; measurement of CAL spots; check axilla/groin.
  2. Ophthalmology Referral: Essential for all (Lisch nodules, optic glioma, retinal hamartomas, glaucoma).
  3. Neuroimaging (MRI):
    • NF1: If symptomatic (vision loss, seizures, rapid head growth).
    • TSC: Baseline MRI brain and abdomen (renal) upon diagnosis.
    • SWS: MRI with contrast to visualize angioma.
  4. Genetic Counseling: Crucial for family planning (AD inheritance patterns).